获取途径

作者

Ren-Yi Su Sun-Bin Ling Qiao-Nan Shan Xu-Yong Wei Rui Wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min Ding Zhi-Dan Xu Lai-Bang Luo Li-Bo Sun Guang-Ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang Qiang He Lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi Guo Liu-Gen Lan Xu-Yong Sun Dong Chen Zhi-Shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo Wang Jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan Wang Zi-Qiang Li Mu-Jian Teng Jun-Jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-Hua Song Zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng Xiao Xu

作者单位

⁴Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou 310022, China ²²Department of Hepatobiliary and Pancreatic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo 315041, China ²Contributed equally. ²⁵Liver Transplant Department, Tianjin First Center Hospital, Tianjin 300192, China ²³Liver Transplant Center, General Hospital of Eastern Theater Command, Nanjing 210002, China ³³Department of Hepatobiliary Surgery, Zhongshan City People's Hospital, Zhongshan 528499, China ³⁴Department of Liver Transplantation Center, The Second Xiangya Hospital of Central South University, Changsha 410011, China ²⁸Liver Transplantaiton Center, Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China ¹Department of Hepatobiliary and Pancreatic Surgery, The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China ¹⁴Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ²⁴Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China ²⁷Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China ⁷Liver Transplantation Center, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China ⁹Department of General Surgery, Xiang'an Hospital of Xiamen University, Xiamen 361000, China ³NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, China ¹⁵Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Zhongnan Hospital of Wuhan University, Wuhan 430071, China ²¹Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China ³⁰Department of Hepatobiliary Surgery, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of USTC Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China ¹⁰Deartment of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China ¹⁸Organ Transplantation Center, Affiliated Hospital of Qingdao University, 59 Haier Road, Laoshan District, Qingdao 266061, China ¹²Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China ⁵Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China ¹³Department of Liver Transplantation, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530000, China ²⁶Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China ⁶Department of Transplantation, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang 330006, China ³⁵Department of Hepatic Surgery and Liver Transplantation Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510062, China ³¹Department of Liver Surgery & Transplantation, Zhongshan Hospital Fudan University, Shanghai 200032, China ¹⁷Liver Transplantation Center, Tsinghua Changgung Hospital, Beijing 102218, China ⁸Department of Hepatic Surgery, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital ¹⁶Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China ²⁰Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China ³²Department of hepato-biliary-pancreatic surgery and liver transplantation center, the First People’ s Hospital of Kunming, Kunming 650000, China ²⁹Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun 130021, China ¹⁹Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610044, China The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518112, China ¹¹Department of Hepatic Surgery and Liver Transplantation Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

刊名

Hepatobiliary & Pancreatic Diseases International

年份

2022

卷号

Vol.21 No.2

页码

106-112

ISSN

1499-3872

关键词

Conversion Hepatocellular carcinoma Immunosuppressive agents Liver transplantation Sirolimus.

摘要

Mammalian target of rapamycin inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival in hepatocellular carcinoma patients beyond the Milan criteria after LT. This is an open-labeled, si...更多

Mammalian target of rapamycin inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival in hepatocellular carcinoma patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specific for the first 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefits for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data. Trial register: Trial registered at http://www.chictr.org.cn: ChiCTR2100042869.收起

文献类型

期刊